Merck Announces WELIREG® (belzutifan) Phase 3 LITESPARK-005 Trial Met Primary Endpoint of Progression-Free Survival in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma - Merck
merck.comSubmitted by merckcom3067 in business
First positive Phase 3 results for WELIREG from LITESPARK-005 showed statistically significant improvements in PFS versus everolimus in these patients Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results fro…